title: Valuing vaccines: deficiencies and remedies.
abstract: Current evaluation models for the value of vaccines typically account for a small subset of the full social and economic benefits of vaccination. Health investments yield positive economic benefits via several channels at the household, community, and national levels. Underestimating, or worse, not considering these benefits can lead to ill-founded recommendations regarding the introduction of vaccines into immunization programs. The clear and strong links between health and wealth suggest the need to redesign valuation frameworks for vaccination so that the full costs may be properly weighed against the full benefits of vaccines.
authors.affiliation: Clarence James Gamble Professor of Economics and Demography, Department of Global Health and Population, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Building 1 12th Floor, Suite 1202 Boston, MA 02115, United States. Electronic address: dbloom@hsph.harvard.edu.
authors.forename: David E
authors.initials: DE
authors.lastname: Bloom
mesh_terms: D003362:Cost-Benefit Analysis / Q000379:methods*; D006291:Health Policy; D006801:Humans; D017589:Immunization Programs / Q000191:economics* / Q000458:organization & administration*; D014611:Vaccination / Q000191:economics* / Q000379:methods*; D014612:Vaccines / Q000191:economics* / Q000276:immunology*
chemical_list: D014612:Vaccines
keywords: Benefit–cost analysis; Cost-effectiveness analysis; Valuation